Freedom Meditech Presents Data Showing Benefits of Non-invasive Diabetes Screening and Glucose Monitoring in the Eye at London ConferenceJanuary 25, 2010 – People with diabetes or at risk of developing the disease – now estimated at over 400 million globally - could reduce complications, improve quality of life and reduce healthcare costs by using new non-invasive technology to screen for and monitor the illness, according to a presentation by Freedom Meditech at the 6th Annual Diabetes and Diabetic Retinopathy Conference in London, England.
“We believe that our proprietary technologies, which non-invasively measure changes in the eye to detect and monitor diabetes, could identify the presence of the disease earlier, and once found, reduce the pain and inconvenience barriers currently required to maintain optimal glycemic control,” said Craig Misrach, President & CEO of Freedom Meditech. “Early disease detection and maintaining tight glucose control are two important keys to reducing the proliferation and associated costs of diabetes complications such as diabetic retinopathy, macular degeneration, and blindness.” Diabetes complications directly attribute to over $120 billion in excess medical expenditures in the United States annually (American Diabetes Association, 2007).
Freedom Meditech is developing two products that non-invasively scan the eye with light to screen for diabetes and monitor glucose levels. The diabetes screening product, which targets an estimated $2 billion untapped market, is designed for use by ophthalmic care practitioners – a market entry point where diabetes can first present in patients. In clinical studies, the device has demonstrated the ability to detect diabetes rapidly, without a blood draw, and before complications become advanced. The company’s glucose monitoring technology targets a $10 billion market and is designed as a handheld device that a person with diabetes gazes into for a reading. Both devices are in the development stage... [PDF] Freedom Meditech's Press Release -
